SOX2 and central nervous system cancer: SOX2-based reporter systems were previously used to demonstrate the CSC phenotype of SOX2-expressing subpopulations in glioma, breast, prostate, bladder or head and neck cancers [4,8,24,26,27,28,29,30,31], although this strategy remained unexplored in sarcomas.